CD22 and colorectal carcinoma: A diversity of immunotoxins has been broadly explored in various tumors including CRC preclinically and clinically, such as FDA-approved moxetumomab pasudotox and ongoing clinical trial RG7787, both of which are PE-based immunotoxins targeting CD22 and mesothelin, respectively [27,28].